MX2021006982A - Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. - Google Patents

Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.

Info

Publication number
MX2021006982A
MX2021006982A MX2021006982A MX2021006982A MX2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A
Authority
MX
Mexico
Prior art keywords
organophosphorus
met inhibitors
therapeutic uses
substituted compounds
triazolo
Prior art date
Application number
MX2021006982A
Other languages
English (en)
Inventor
Jirong Peng
Don Zhang
Michael Alan Green
Michael John Costanzo
Michael Nicholas Greco
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of MX2021006982A publication Critical patent/MX2021006982A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/50Organo-phosphines
    • C07F9/5004Acyclic saturated phosphines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32Esters thereof
    • C07F9/3205Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211Esters of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación provee derivados de [1,2,4]triazolo[4,3-b] [1,2,4]triazina, [1,2,4]triazolo[4,3-b]piridazina y [1,2,3]triazolo[4,5-b]pirazina, y sales, solvatos o profármacos farmacéuticamente aceptables de los mismos, como inhibidores de la tirosina cinasa c-MET, los cuales son útiles como agentes anticancerosos y/o antiinflamatorios novedosos.
MX2021006982A 2018-12-14 2019-12-14 Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. MX2021006982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779960P 2018-12-14 2018-12-14
PCT/US2019/066414 WO2020124060A1 (en) 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2021006982A true MX2021006982A (es) 2021-09-10

Family

ID=71077551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006982A MX2021006982A (es) 2018-12-14 2019-12-14 Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.

Country Status (15)

Country Link
US (1) US20220064194A1 (es)
EP (1) EP3893872B1 (es)
JP (1) JP2022513215A (es)
KR (1) KR20210111779A (es)
CN (1) CN113412112B (es)
AU (1) AU2019395282A1 (es)
BR (1) BR112021011547A2 (es)
CA (1) CA3122575A1 (es)
EA (1) EA202191541A1 (es)
IL (1) IL283589A (es)
MX (1) MX2021006982A (es)
SG (1) SG11202105872RA (es)
TW (1) TW202039500A (es)
WO (1) WO2020124060A1 (es)
ZA (1) ZA202104000B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620292B1 (pt) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA025466B1 (ru) 2009-12-31 2016-12-30 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
JP6659850B2 (ja) * 2015-12-31 2020-03-04 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途

Also Published As

Publication number Publication date
WO2020124060A1 (en) 2020-06-18
EP3893872A1 (en) 2021-10-20
CN113412112B (zh) 2024-06-11
CA3122575A1 (en) 2020-06-18
JP2022513215A (ja) 2022-02-07
CN113412112A (zh) 2021-09-17
AU2019395282A1 (en) 2021-07-08
ZA202104000B (en) 2022-08-31
IL283589A (en) 2021-07-29
EP3893872A4 (en) 2022-08-10
EA202191541A1 (ru) 2022-01-21
US20220064194A1 (en) 2022-03-03
BR112021011547A2 (pt) 2021-08-31
TW202039500A (zh) 2020-11-01
SG11202105872RA (en) 2021-07-29
KR20210111779A (ko) 2021-09-13
EP3893872B1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
PH12019500775A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PH12019500776A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12019501670A1 (en) Kras g12c inhibitors and methods of using the same
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
MX2021009439A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
MX2018002916A (es) Metodos, composiciones y usos de nuevos inhibidores de fyn quinasa.
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
MX2021006982A (es) Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
MX2020010084A (es) Composiciones farmaceuticas anticancerigenas para terapia combinada.
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201990939A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ